Abstract:All organisms growing beyond the oxygen diffusion limit critically depend on a functional vasculature for survival. Yet blood vessels are far more than passive, uniform conduits for oxygen and nutrient supply. A remarkable organotypic heterogeneity is brought about by tissue-specific differentiated endothelial cells (lining the blood vessels’ lumen) and allows blood vessels to deal with organ-specific demands for homeostasis. On the flip side, when blood vessels go awry, they promote life-threatening diseases characterized by endothelial cells inappropriately adopting an angiogenic state (eg, tumor vascularization) or becoming dysfunctional (eg, diabetic microvasculopathies), calling respectively for antiangiogenic therapies and proangiogenic/vascular regenerative strategies. In solid tumors, despite initial enthusiasm, growth factor–based (mostly anti-VEGF [vascular endothelial growth factor]) antiangiogenic therapies do not sufficiently live up to the expectations in terms of efficiency and patient survival, in part, due to intrinsic and acquired therapy resistance. Tumors cunningly deploy alternative growth factors than the ones targeted by the antiangiogenic therapies to reinstigate angiogenesis or revert to other ways of securing blood flow, independently of the targeted growth factors. In trying to alleviate tissue ischemia and to repair dysfunctional or damaged endothelium, local in-tissue administration of (genes encoding) proangiogenic factors or endothelial (stem) cells harnessing regenerative potential have been explored. Notwithstanding evaluation in clinical trials, these approaches are often hampered by dosing issues and limited half-life or local retention of the administered agents. Here, without intending to provide an all-encompassing historical overview, we focus on some recent advances in understanding endothelial cell behavior in health and disease and identify novel molecular players and concepts that could eventually be considered for therapeutic targeting.

Vascular Endothelial Growth Factor: A Translational View in Oral Non-Communicable Diseases

VEGF Mediated Signaling in Oral Cancer

Vascular Endothelial Growth Factor and Atherosclerosis

Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer.

Biology and therapeutic targeting of vascular endothelial growth factor A

VEGF in Signaling and Disease: Beyond Discovery and Development

Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance

Effects of Angiogenic Factors on the Epithelial-to-Mesenchymal Transition and Their Impact on the Onset and Progression of Oral Squamous Cell Carcinoma: An Overview

The biology of VEGF and its receptors

Vascular endothelial growth factor signaling in development and disease

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

The Vascular Endothelial Growth Factor Family and Antiangiogesis Therapy

The Impact of VEGF on Cancer Metastasis and Systemic Disease.

Chronic Inflammation and Colorectal Cancer: the Role of Vascular Endothelial Growth Factor

VEGFA and tumour angiogenesis

Basic and Therapeutic Aspects of Angiogenesis Updated

Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role

VEGF Signal System: the Application of Antiangiogenesis.

Extracellular Vesicles in Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review

VEGF in biological control

The Role of the VEGF Signaling Pathway in Tumor Angiogenesis